SubHero Banner

Abecma (idecabtagene vicleucel) – New orphan drug approval

March 27, 2021 - The FDA announced the approval of Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Download PDF